Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14605637 | 1.00 | TSHR (0.56) | TSHRFKBP1AALDH1A1BACE1FABP7 | |
| SCHEMBL5461273 | 1.00 | TSHR (0.56) | TSHRFKBP1AALDH1A1BACE1FABP7 | |
| SCHEMBL6871388 | 1.00 | TSHR (0.56) | TSHRFKBP1AALDH1A1BACE1FABP7 | |
| SCHEMBL9169159 | 1.00 | TSHR (0.56) | TSHRFKBP1AALDH1A1BACE1FABP7 | |
| SCHEMBL13314011 | 1.00 | TSHR (0.56) | TSHRFKBP1AALDH1A1BACE1FABP7 | |
| SCHEMBL14605828 | 1.00 | TSHR (0.56) | TSHRFKBP1AALDH1A1BACE1FABP7 | |
| SCHEMBL9733234 | 1.00 | TSHR (0.56) | TSHRFKBP1AALDH1A1BACE1FABP7 | |
| SCHEMBL13889276 | 1.00 | TSHR (0.56) | TSHRFKBP1AALDH1A1BACE1FABP7 | |
| SCHEMBL14117906 | 1.00 | TSHR (0.56) | TSHRFKBP1AALDH1A1BACE1FABP7 | |
| SCHEMBL14117911 | 1.00 | TSHR (0.56) | TSHRFKBP1AALDH1A1BACE1FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104045593-B | A kind of preparation method of trandolapril intermediate | 上海交通大学 | 2016-11-02 | — | — | CN | claimed |
| CN-104045593-A | Trandolapril intermediate preparation method | UNIV SHANGHAI JIAOTONG | 2014-09-17 | — | — | CN | claimed |
| EP-1866327-A1 | IMPROVED PROCESS FOR PREPARATION OF HIGHLY PURE TRANDOLAPRIL | Lupin Ltd. (IN) | 2007-12-19 | — | — | EP | claimed |
| WO-2006085332-A1 | IMPROVED PROCESS FOR PREPARATION OF HIGHLY PURE TRANDOLAPRIL | LUPIN LIMITED (IN) | 2006-08-17 | — | — | WO | claimed |
| CN-104045593-B | A kind of preparation method of trandolapril intermediate | 上海交通大学 | 2016-11-02 | — | — | CN | disclosed |
| CN-102887853-B | A kind of preparation method of trandolapril intermediate | SHANGHAI JIAO TONG UNIVERSITY (CN) | 2016-01-13 | — | — | CN | disclosed |
| CN-104045593-A | Trandolapril intermediate preparation method | UNIV SHANGHAI JIAOTONG | 2014-09-17 | — | — | CN | disclosed |
| CN-102887853-A | Method for preparing trandolapril intermediate | UNIV SHANGHAI JIAOTONG | 2013-01-23 | — | — | CN | disclosed |
| US-7973173-B2 | Process for the synthesis of an ACE inhibitor | CIPLA LIMITED (IN) | 2011-07-05 | — | — | US | disclosed |
| US-7521566-B2 | Process for preparation of perindopril and salts thereof | LES LABORATOIRES SERVIER (FR) | 2009-04-21 | — | — | US | disclosed |
| US-20090069574-A1 | Process for the synthesis of an ace inhibitor | CIPLA LIMITED (IN) | 2009-03-12 | — | — | US | disclosed |
| CN-100404548-C | Novel method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof | SERVIER LAB (FR) | 2008-07-23 | — | — | CN | disclosed |
| EP-1603558-A1 | PROCESS FOR PREPARATION OF PERINDOPRIL AND SALTS THEREOF | Lupin Limited (IN) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005108365-A1 | PROCESSES FOR THE PREPARATION OF ALPHA POLYMORPH OF PERINDOPRIL ERBUMINE | GLENMARK PHARMACEUTICALS LIMITED (US) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005068425-A1 | NEW CRYSTALLINE FORM OF PERINDOPRIL | LEK PHARMACEUTICALS D.D. (SI) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005019173-A1 | PROCESS FOR PURE PERINDOPRIL TERT-BUTYLAMINE SALT | HETERO DRUGS LIMITED (IN) | 2005-03-03 | — | — | WO | disclosed |
| WO-2004075889-A1 | PROCESS FOR PREPARATION OF PERINDOPRIL AND SALTS THEREOF | LUPIN LIMITED (IN) | 2004-09-10 | — | — | WO | disclosed |
| US-5401766-A | Hypotensive agents with vasodilation | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-03-28 | — | — | US | disclosed |
| US-5162362-A | Hypotensive agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-11-10 | — | — | US | disclosed |
| US-5158959-A | Treatment of hypertension | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069574-A1 | Process for the synthesis of an ace inhibitor | ACE, ACE2, AGTR1 | TSHR 2558/4885FKBP1A 1778/4885ALDH1A1 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.